Belimumab: The first US FDA approved biological therapy for systemic lupus erythematosus

International Journal of Clinical Rheumatology

Volumn 6, Issue 4, 2011, Pages 373-377

  Mok, Chi Chiu ^a  

^a TUEN MUN HOSPITAL   (Hong Kong)

Author keywords

B cell depletion; BAFF; biologics; immunomodulation; lupus; novel; targeted therapy; therapeutics; therapy

Indexed keywords

ABATACEPT; ABETIMUS; ATACICEPT; BELIMUMAB; EPRATUZUMAB; OCRELIZUMAB; PLACEBO; PREDNISONE; RITUXIMAB;

B LYMPHOCYTE ACTIVATION; BIOLOGICAL THERAPY; CLINICAL EFFECTIVENESS; COST EFFECTIVENESS ANALYSIS; DEPRESSION; DISEASE EXACERBATION; DOSE RESPONSE; DRUG APPROVAL; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG EFFICACY; DRUG FATALITY; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; FOOD AND DRUG ADMINISTRATION; HUMAN; IMMUNOMODULATION; INJECTION SITE REACTION; MAINTENANCE THERAPY; MALIGNANT NEOPLASTIC DISEASE; MOLECULAR PATHOLOGY; NONHUMAN; OPPORTUNISTIC INFECTION; PRIORITY JOURNAL; REVIEW; SYSTEMIC LUPUS ERYTHEMATOSUS; TREATMENT DURATION; UNITED STATES;

EID: 80051957052     PISSN: 17584272     EISSN: 17584280     Source Type: Journal    
DOI: 10.2217/ijr.11.33     Document Type: Review

References (25)

1. Mok CC, Lau CS. Pathogenesis of systemic lupus erythematosus. J. Clin. Pathol. 56, 481-490 (2003).
2. Katsiari CG, Liossis SN, Sfikakis PP. The pathophysiologic role of monocytes and macrophages in systemic lupus erythematosus: A reappraisal. Semin. Arthritis Rheum. 39, 491-503 (2010).
3. Fransen JH, van der Vlag J, Ruben J, Adema GJ, Berden JH, Hilbrands LB. The role of dendritic cells in the pathogenesis of systemic lupus erythematosus. Arthritis Res. Ther. 12(2), 207 (2010).
4. Scheinecker C, Bonelli M, Smolen JS. Pathogenetic aspects of systemic lupus erythematosus with an emphasis on regulatory T cells. J. Autoimmun. 35, 269-275 (2010).
5. Jacob N, Stohl W. Autoantibody-dependent and autoantibody-independent roles for B cells in systemic lupus erythematosus: Past, present, and future. Autoimmunity 43, 84-97 (2010).
6. Horton CG, Pan ZJ, Farris AD. Targeting Toll-like receptors for treatment of SLE. Mediators Inflamm. pii 498980 (2010).
7. Grammer AC, Lipsky PE. B cell abnormalities in systemic lupus erythematosus. Arthritis Res. Ther. 5(Suppl. 4), 2-7 (2003).
8. Odendahl M, Jacobi A, Hansen A et al. Disturbed peripheral B lymphocyte homeostasis in systemic lupus erythematosus. J. Immunol. 165, 5970-5979 (2000).
9. Jacobi AM, Reiter K, Mackay M et al. Activated memory B cell subsets correlate with disease activity in systemic lupus erythematosus: Delineation by expression of CD27, IgD, and CD95. Arthritis Rheum. 58, 1762-1773 (2008).
10. Wei C, Anolik J, Cappione A et al. A new population of cells lacking expression of CD27 represents a notable component of the B cell memory compartment in systemic lupus erythematosus. J. Immunol. 178, 6624-6633 (2007).
11. Mamula MJ, Fatenejad S, Craft J. B cells process and present lupus autoantigens that initiate autoimmune T cell responses. J. Immunol. 152, 1453-1461 (1994).
12. Pistoia V. Production of cytokines by human B cells in health and disease. Immunol. Today 18, 343-350 (1997).
13. Wong CK, Wong PT, Tam LS, Li EK, Chen DP, Lam CW. Elevated production of B cell chemokine CXCL13 is correlated with systemic lupus erythematosus disease activity. J. Clin. Immunol. 30, 45-52 (2010).
14. Mok CC. Update on emerging drug therapies for systemic lupus erythematosus. Expert Opin. Emerg. Drugs 15, 53-70 (2010).
15. Moore PA, Belvedere O, Orr A et al. BLyS: Member of the tumor necrosis factor family and B lymphocyte stimulator. Science 285, 260-263 (1999).
16. Petri M, Stohl W, Chatham W et al. Association of plasma B lymphocyte stimulator levels and disease activity in systemic lupus erythematosus. Arthritis Rheum. 58, 2453-2459 (2008).
17. Collins CE, Gavin AL, Migone TS, Hilbert DM, Nemazee D, Stohl W. B lymphocyte stimulator (BLyS) isoforms in systemic lupus erythematosus: Disease activity correlates better with blood leukocyte BLyS mRNA levels than with plasma BLyS protein levels. Arthritis Res. Ther. 8(1), R6 (2006).
18. Baker KP, Edwards BM, Main SH et al. Generation and characterization of LymphoStat-B, a human monoclonal antibody that antagonizes the bioactivities of B lymphocyte stimulator. Arthritis Rheum. 48, 3253-3265 (2003).
19. Wallace DJ, Stohl W, Furie RA et al. A Phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus. Arthritis Rheum. 61, 1168-1178 (2009).
20. Furie R, Stohl W, Ginzler EM et al. Biologic activity and safety of belimumab, a neutralizing anti-B-lymphocyte stimulator (BLyS) monoclonal antibody: A Phase I trial in patients with systemic lupus erythematosus. Arthritis Res. Ther. 10, R109 (2008).
21. Merrill JT, Wallace DJ, Furie RA et al. The LBSL02/99 Study Group. Five-year experience with belimumab, a BLyS-specific inhibitor, in patients with systemic lupus erythematosus (SLE). Arthritis Rheum. 62(Suppl. 10), S608 (Abstract 1457).
22. Navarra SV, Guzmán RM, Gallacher AE et al. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: A randomised, placebo-controlled, Phase 3 trial. Lancet 377, 721-731 (2011).
23. Furie RA, Zamani O, Wallace DJ et al. BLISS-76 Study group. Belimumab, a BLyS-specific inhibitor, reduced disease activity and severe flares in seropositive SLE patients: BLISS-76 study results through wk 76. Arthritis Rheum. 62 (Suppl. 10), S606 (Abstract 1454) (2010).
24. Hiepe F, Stohl W, Scheinberg MA et al. BLISS-52 and BLISS-76 Study groups. The mechanism of action of belimumab, a BLyS-specific inhibitor, is consistent with biomarker and vaccine results from the Phase 3 BLISS studies. Ann. Eur. Cong. Rheumatol.(2011) (Abstract OP0166).
25. Vollenhoven R, Schneider M, Wallace DJ et al. BLISS-52 and BLISS-76 Study groups. Efficacy of belimumab in patients with SLE: Focus on patients with low complement and positive anti-dsDNA - results from BLISS-52/BLISS-76. Ann. Eur. Cong. Rheumatol. (2011) (Abstract OP0167).